Symbolbild · KI-generiert
Arch Biopartners Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Arch Biopartners Inc. is a therapeutic biotechnology company developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The Company is advancing an integrated program that includes new treatments targeting inflammation- and toxin-related kidney injury. Arch's development pipeline includes: LSALT peptide: in a Phase II trial targeting cardiac surgery-associated AKI. Cilastatin: a repurposed drug in a Phase II trial targeting toxin-induced AKI. CKD Platform: next-generation therapeutics targeting chronic kidney disease. These assets represent distinct, mechanism-based approaches focused on protecting the kidney from different causes of damage. Chronic kidney disease affects more than 800 million people worldwide, while acute kidney injury adds a further significant burden. Together, Arch's programs target unmet needs across both acute and chronic kidney disease.
Company description as published by the issuer via TMX Money.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Arch Biopartners Inc. | ARCH | TSXV | 39 Mio. USD |
| Planet 13 Holdings Inc. | PLTH | CSE | 38 Mio. USD |
| Decibel Cannabis Company Inc. | DB | TSXV | 41 Mio. USD |
| BioMark Diagnostics Inc. | BUX | CSE | 43 Mio. USD |
| Dividend Select 15 Corp. Equity Shares | DS | TSX | 35 Mio. USD |
| Ocumetics Technology Corp. | OTC | TSXV | 43 Mio. USD |
| Covalon Technologies Ltd. | COV | TSXV | 44 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.